DRUG COMPANIES TAKE CONTROL

摘要

The pharmaceutical industry, responding to a simultaneous push from the market and pull from regulators, is taking tentative first steps toward the state of the art in automated manufacturing control and analysis.rnThe steps are a response to investor calls for cost control and to a new program from the Food 8c Drug Administration that eases the regulatory burden of making changes to validated manufacturing systems. According to managers at both drug and control systems companies, these steps are taking the industry away from a labor- and paperwork-intensive production regime toward a more streamlined world in which data analysis and process development are integrated from drug discovery to product launch.